Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares

Inhibrx Biosciences, Inc. (NASDAQ:INBX) shareholders (or potential shareholders) will be happy to see that the Founder, Mark Lappe, recently bought a whopping US$2.6m worth of stock, at a price of US$106. While that only increased their holding size by 2.7%, it is still a big swing by our standards.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Inhibrx Biosciences Insider Transactions Over The Last Year

In fact, the recent purchase by Mark Lappe was the biggest purchase of Inhibrx Biosciences shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of US$113 per share to be enticing. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Inhibrx Biosciences share holders is that insiders were buying at near the current price.

In the last twelve months Inhibrx Biosciences insiders were buying shares, but not selling. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

View our latest analysis for Inhibrx Biosciences

Inhibrx Biosciences is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership Of Inhibrx Biosciences

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Inhibrx Biosciences insiders own about US$252m worth of shares (which is 15% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Do The Inhibrx Biosciences Insider Transactions Indicate?

It's certainly positive to see the recent insider purchases. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest Inhibrx Biosciences insiders are well aligned, and quite possibly think the share price is too low. Nice! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Inhibrx Biosciences. While conducting our analysis, we found that Inhibrx Biosciences has 3 warning signs and it would be unwise to ignore these.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.